Dendreon/Corvas Deal Follows 2003 Merger Theme: Biotech Cash Has Caché
Executive Summary
Dendreon is adding a second R&D campus at essentially no cost via the proposed acquisition of Corvas
You may also be interested in...
NPS/Enzon Merger Provides Additional Leverage In Search For Preos Partner
The NPS/Enzon $1.6 bil. merger deal provides more leverage to the companies' search for a partner for the osteoporosis treatment Preos
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials